[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Mosqueda Taylor A, Meneses García A, Ruíz Godoy Rivera LM, Suárez Roa Mde L, Luna Ortiz K: Malignant odontogenic tumors. A retrospective and collaborative study of seven cases. Med Oral; 2003 Mar-Apr;8(2):110-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were seven cases (5 male and 2 female patients), which represent less than 4% of all odontogenic tumors diagnosed in these services.
  • There were six odontogenic carcinomas (two malignant ameloblastomas, two clear cell odontogenic carcinomas, one primary intraosseous carcinoma and one carcinoma arising in an odontogenic cyst) and one ameloblastic fibrosarcoma.
  • Clear cell odontogenic carcinomas occurred in the canine-premolar region, one in the maxilla and one in the mandible (one ia a man and one in a woman), while the remaining lesions affected the posterior region of the mandible, with a male predominance (4:1), which agrees with previously reported cases.
  • Surgical resection was the treatment employed in all carcinomas, while the ameloblastic fibrosarcoma was treated with chemotherapy due to its large extension, but without favorable response.
  • The patient with primary intraosseous carcinoma had submaxillary and cervical metastases and the neoplasm was the cause of death.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Ameloblastoma / pathology. Female. Humans. Male. Mandibular Neoplasms / pathology. Middle Aged. Odontogenic Cysts / pathology. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12618671.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


2. Ram H, Mohammad S, Husain N, Gupta PN: Ameloblastic carcinoma. J Maxillofac Oral Surg; 2010 Dec;9(4):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic carcinoma (AC) is a rare aggressive malignant epithelial odontogenic tumor of the maxillofacial skeleton with a distinct predilection in the mandible.
  • It may appear de novo or originate from a pre-existing ameloblastoma or odontogenic cyst.
  • It exhibits cytological features of ameloblastoma and carcinoma.
  • It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.
  • Direct extension of the tumour, lymph node involvement and metastasis to various sites has been reported.
  • Wide local excision is the treatment of choice.
  • Regional lymph node dissection should be considered and performed selectively.
  • Radiotherapy and chemotherapy have limited role in the treatment of ameloblastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190836.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177477
  • [Keywords] NOTNLM ; Ameloblastic carcinoma / Ameloblastoma / Odontogenic tumor
  •  go-up   go-down


3. Diba R, Saadati H, Esmaeli B: Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck; 2005 Jan;27(1):72-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The tumor diagnoses were squamous cell carcinoma (n = 18), chondrosarcoma (n = 3), sinonasal carcinoma (n = 2), adenoid cystic carcinoma (n = 2), sinonasal papilloma (n = 2), esthesioneuroblastoma (n = 1); hemangiopericytoma (n = 1); ameloblastoma (n = 1), and osteosarcoma (n = 1).
  • Twenty-eight patients had a maxillectomy or other sinus surgeries, 10 had radiotherapy, and 14 had chemotherapy and radiotherapy before DCR.
  • CONCLUSIONS: DCR alleviates nasolacrimal duct blockage in most patients with head and neck tumors and is not associated with unusual complications in this setting.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Ethmoid Bone / surgery. Female. Humans. Male. Maxilla / surgery. Middle Aged. Paranasal Sinuses / surgery. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15565560.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kelly JM, Belding BA, Schaefer AK: Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin. Vet Comp Oncol; 2010 Jun;8(2):81-6
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acanthomatous ameloblastoma in dogs treated with intralesional bleomycin.
  • Acanthomatous ameloblastoma (AA) is a benign gingival tumour that often invades bone.
  • This retrospective study evaluated the efficacy of intralesional (IL) bleomycin as a treatment for AA.
  • Six dogs received weekly or bimonthly IL bleomycin injections (dose range, 10-20 U m(-2)).
  • One to sixteen treatments were administered (median, 5).
  • Six of the seven dogs had a complete response within 4 months from initial IL injection (median, 1.5 months), whereas the palliative case had approximately 25% decrease in tumour volume 14 days from initial injection.
  • Local recurrence was not observed during the study period, with a median follow-up time of 842 days.
  • Adverse effects were limited to wound formation with bone exposure (n = 4), mild tissue reactions (n = 3), local swelling (n = 2) and local infection (n = 1).
  • The conclusions of this study show IL bleomycin is an effective treatment for canines with AA.
  • [MeSH-major] Ameloblastoma / veterinary. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dog Diseases / drug therapy. Gingival Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Injections, Intralesional / veterinary. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20579320.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


5. Kitsoulis P, Charchanti A, Paraskevas G, Marini A, Karatzias G: Adamantinoma. Acta Orthop Belg; 2007 Aug;73(4):425-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adamantinoma.
  • Adamantinoma is one of the rarest low-grade malignant bone tumours, representing less than 1% of them.
  • Fisher in 1913 named this tumour adamantinoma because of its similarity to ameloblastoma of the jaw.
  • Other long bones not uncommonly affected are the humerus, ulna, femur, fibula and radius.
  • The symptoms are not specific but most frequently the patient complains about swelling, redness, pain and sensitivity of the bone where the tumour is located.
  • Young males are more prone to develop adamantinoma than females.
  • The tumour usually spreads to the lungs, the regional lymph nodes, or other bones.
  • Wide tumour excision and limb salvage reconstruction surgery, or an amputation, are the current surgical treatment options.
  • Radiotherapy and chemotherapy have not been shown to be effective modalities of treatment.
  • [MeSH-major] Adamantinoma. Bone Neoplasms
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939469.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 58
  •  go-up   go-down


6. Fujii H, Honoki K, Enomoto Y, Kasai T, Kido A, Amano I, Kumamoto M, Morishita T, Mii Y, Nonomura A, Takakura Y: Adamantinoma-like Ewing's sarcoma with EWS-FLI1 fusion gene: a case report. Virchows Arch; 2006 Nov;449(5):579-84
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adamantinoma-like Ewing's sarcoma with EWS-FLI1 fusion gene: a case report.
  • Recent studies have advocated the genotypic and phenotypic delineation of a novel Ewing's sarcoma histologic variant showing epithelial features defined as "adamantinoma-like Ewing's sarcoma".
  • We described an 18-year-old girl with a primary small round-cell sarcoma of the right tibia showing polyphenotypic differentiation with epithelioid features.
  • The neoplastic cells had mainly round or oval nuclei with fine chromatin with a portion of epithelial arrangements.
  • The immunohistochemical analysis showed the epithelial markers of cytokeratin 5/6/18, AE1/AE3, and cytokeratin high molecular weight were stained especially in the foci with epithelioid features, as well as MIC2, S100, and NSE.
  • The diagnosis of the lesion was confirmed as Ewing's sarcoma by the presence of the EWS-FLI1 fusion transcript, and could be defined as the so-called "adamantinoma-like Ewing's sarcoma".
  • After wide excision and high-dose chemotherapy with peripheral blood stem cell transfusion, the patient has been well and continuously event-free for 3 years since the initial diagnosis.
  • [MeSH-major] Adamantinoma / pathology. Bone Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1 / genetics. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1979 Dec;166(1):112-22 [551397.001]
  • [Cites] C R Seances Acad Sci III. 1983;296(23):1105-7 [6416623.001]
  • [Cites] Am J Surg Pathol. 1981 Sep;5(6):533-42 [7325273.001]
  • [Cites] Med Pediatr Oncol. 2003 May;40(5):276-87 [12652615.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] CA Cancer J Clin. 1972 Mar-Apr;22(2):95-8 [4622125.001]
  • [Cites] Am J Surg Pathol. 1993 Dec;17(12):1225-33 [7694513.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):271-7 [1283315.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23(7):501-7 [7824975.001]
  • [Cites] Cancer Genet Cytogenet. 1984 May;12(1):1-19 [6713356.001]
  • [Cites] Skeletal Radiol. 1992;21(3):205-9 [1604351.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):698-708 [1730120.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1911-8 [8410118.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1530-7 [14657712.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1975;365(1):63-74 [804740.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1482-8 [8101562.001]
  • [Cites] Skeletal Radiol. 1983;10 (1):61-6 [6879221.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):410-6 [10716155.001]
  • [Cites] J Pathol. 2001 Sep;195(2):218-21 [11592101.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23 (2):159-65 [9989842.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):317-25 [1867320.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3072-8 [12915596.001]
  • [Cites] Am J Pathol. 1987 May;127(2):288-304 [2437802.001]
  • [Cites] J Bone Joint Surg Am. 1994 Oct;76(10):1482-99 [7929496.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):215-37 [3514033.001]
  • (PMID = 17016721.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  •  go-up   go-down


7. Sauk JJ, Nikitakis NG, Scheper MA: Are we on the brink of nonsurgical treatment for ameloblastoma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul;110(1):68-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are we on the brink of nonsurgical treatment for ameloblastoma?
  • OBJECTIVE: Recent identification of altered molecular signaling pathways in neoplasia has begun to elucidate mechanisms of oncogenesis, differentiation, and tumor progression, and to suggest plausible nonsurgical considerations for treatment.
  • Here we review the sonic hedgehog (SHH) and PI3K/Akt/mTOR signaling pathways, their role in ameloblastoma, a locally aggressive odontogenic tumor, and evidence for consideration of therapeutic approaches that target these molecular pathways.
  • STUDY DESIGN: This is a comprehensive review of the literature regarding alterations in signaling mechanisms associated with ameloblastomas.
  • In addition, this review attempts to explore and discuss possible inhibitors to these pathways that may have utility in treating ameloblastoma.
  • RESULTS: The expression of SHH signaling molecules in ameloblastomas at the mRNA and protein levels has intimated that these molecules may play a role in cell proliferation of these tumors.
  • Immunohistochemical analysis has revealed aberrant signaling in the PI3K/Akt/mTOR pathway in ameloblastomas and appears to be a valuable tool for elucidating pathogenesis and aggressiveness, and selecting optimal therapeutics.
  • CONCLUSION: The understanding of altered pathways in ameloblastoma may soon provide nonsurgical options for the treatment of this condition.
  • Thus, tumors that entirely depend on active SHH signaling for survival/growth and maintenance may well be susceptible targets for combined chemotherapy with SHH-specific inhibitors together with PI3K, Akt, or mTOR blocking agents.
  • [MeSH-major] Ameloblastoma / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Hedgehog Proteins / antagonists & inhibitors. Hedgehog Proteins / physiology. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / physiology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / physiology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / physiology. TOR Serine-Threonine Kinases. Transcription Factors / antagonists & inhibitors. Transcription Factors / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20418126.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / SHH protein, human; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


8. Nishimori H, Takahashi S, Nagasaki E, Kobayashi T, Yokoyama M, Shinozaki E, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Inamura K, Hatake K: [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]. Gan To Kagaku Ryoho; 2005 May;32(5):671-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
  • A 40-year-old man suffering from right cheek swelling was first diagnosed with ameloblastoma or anaplastic poorly-differentiated carcinoma of the head and neck region.
  • He received 2 courses of CDDP/TXT chemotherapy (cisplatin 75 mg/m2, docetaxel 80 mg/m2) and achieved a partial response, but his carcinoma of the pancreas recurred.
  • He also achieved a partial response with 2 courses of CBDCA/TXL regimen (carboplatin AUC=6, paclitaxel 200 mg/m2), but later died from his progressive disease.
  • This case was close to a cancer with an unknown primary (CUP) site, and several favorable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy.
  • Poorly-differentiated neuroendocrine carcinomas like this case are highly sensitive to chemotherapy, and a careful pathological diagnosis may clarify its sensitivity to chemotherapy and the prognosis.
  • [MeSH-major] Carcinoma / secondary. Neoplasms, Unknown Primary / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918570.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Sabo D, Bernd L, Buchner M, Treiber M, Wannenmacher M, Ewerbeck V, Parsch D: [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors]. Orthopade; 2003 Nov;32(11):1003-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors].
  • In 13 patients with primary malignant bone tumors (10 Ewing's sarcoma, 1 parosteal osteosarcoma, 1 adamantinoma recurrence, and 1 MFH) local therapy was performed as intraoperative extracorporeal irradiation and replantation (IEIR) of the involved bone segment (5 tibia, 2 femur, and 6 pelvis).
  • Of the 13 patients (69%), 9 are alive at the time of the follow-up (5 CDF, 4 AWM(treated)) and 4 patients died of disease (DOD).
  • IEIR must be seen as an extraordinary reconstruction procedure in cases where established procedures such as endoprosthesis, biological reconstructions, or rotationplasties cannot be used or are refused by the patient.
  • [MeSH-minor] Adolescent. Adult. Aged. Ameloblastoma / drug therapy. Ameloblastoma / pathology. Ameloblastoma / radiotherapy. Ameloblastoma / surgery. Child, Preschool. Combined Modality Therapy. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Follow-Up Studies. Histiocytic Sarcoma / drug therapy. Histiocytic Sarcoma / pathology. Histiocytic Sarcoma / radiotherapy. Histiocytic Sarcoma / surgery. Humans. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / surgery. Radiotherapy Dosage. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / surgery. Tibia / pathology. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1988 May-Jun;200(3):243-52 [3145357.001]
  • [Cites] J Bone Joint Surg Am. 1987 Apr;69(4):583-95 [2952660.001]
  • [Cites] Orthop Clin North Am. 1987 Apr;18(2):275-89 [3550576.001]
  • [Cites] Langenbecks Arch Surg. 2003 Jan;387(9-10):355-65 [12536331.001]
  • [Cites] Acta Orthop Scand. 1996 Dec;67(6):583-8 [9065072.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):613-30 [7046906.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3685-90 [12552977.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):54-64 [7822356.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1992 Jul-Aug;130(4):285-9 [1413973.001]
  • [Cites] J Bone Joint Surg Br. 1988 May;70(3):348-53 [3163694.001]
  • [Cites] J Orthop Res. 1985;3(4):389-404 [3906062.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1017-21 [6883269.001]
  • [Cites] Unfallchirurg. 1999 Jul;102(7):580-8 [10459306.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):223-30 [1884544.001]
  • [Cites] Int Orthop. 1998;22(1):32-6 [9580457.001]
  • [Cites] Int Orthop. 1997;21(5):283-90 [9476156.001]
  • [Cites] Acta Orthop Scand. 1988 Feb;59(1):34-8 [3128053.001]
  • [Cites] J Bone Joint Surg Br. 2000 Mar;82(2):276-82 [10755441.001]
  • [Cites] J Bone Joint Surg Am. 1986 Mar;68(3):362-9 [3456348.001]
  • [Cites] J Bone Joint Surg Am. 1991 Sep;73(8):1123-42 [1890115.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):196-206 [10613169.001]
  • [Cites] Clin Orthop Relat Res. 1993 Oct;(295):226-38 [8403653.001]
  • [Cites] Clin Orthop Relat Res. 1990 Feb;(251):249-53 [2295182.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1991;77(1):6-13 [1829244.001]
  • (PMID = 14615850.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Zhang L, Zeng D, Huang H, Wang J, Tao Q, Pan C, Xu J, Zhang B, Wang A: Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model. J Oral Pathol Med; 2010 Jan;39(1):94-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model.
  • BACKGROUND: Ameloblastomas are odontogenic neoplasms characterized by local invasiveness.
  • This study was conducted to develop a new animal model of ameloblastoma and to address the role of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2) in the growth and invasiveness of ameloblastomas.
  • METHOD: Donated fresh human ameloblastoma tissue was finely minced, screened, and subcutaneously implanted in three locations on each of 10 BALB/c-nu/nu nude mice.
  • Tumors were monitored for 5 weeks and excised for histopathology, RNA, and protein analyses.
  • RESULTS: The ameloblastoma xenografts were established with high frequency and contained a variety of typical features, validating this new model system.
  • CONCLUSIONS: We successfully established a new experimental model of ameloblastoma consisting of subcutaneous human xenografts in nude mice.
  • In addition, we demonstrated the successful introduction of the TIMP-2 gene in tumor xenograft cells in vivo, resulting in xenograft growth inhibition.
  • This growth inhibition may have resulted from TIMP-2 overexpression specifically inhibiting MMP-2 protein expression and activity.
  • [MeSH-major] Ameloblastoma / drug therapy. Neoplasm Transplantation. Soft Tissue Neoplasms / drug therapy. Tissue Inhibitor of Metalloproteinase-2 / therapeutic use. Transplantation, Heterologous
  • [MeSH-minor] Adult. Animals. Blotting, Western. Disease Models, Animal. Female. Genetic Vectors / therapeutic use. Humans. Matrix Metalloproteinase 2. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Plasmids / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction. Subcutaneous Tissue / surgery. Transfection. Tumor Cells, Cultured

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895658.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.24 / Mmp2 protein, mouse
  •  go-up   go-down


11. Diba R, Saadati HG, Esmaeli B: Outcomes of dacrocystorhinostomy in patients with head and neck tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):5584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor diagnoses were as follows: squamous cell carcinoma (SCCA), 18 patients (16 had paranasal-sinus SCCA and 2 had skin SCCA); chondrosarcoma, 3; sinonasal carcinoma, 2; adenoid cystic carcinoma, 2; sinonasal papilloma, 2; esthesioneuroblastoma, 1; hemangiopericytoma,1; ameloblastoma,1; and ostoesarcoma,1.
  • Twenty-one patients had a maxillectomy and 7 patients had other sinus surgeries before DCR.
  • Six patients had had silicone intubation at the time of maxillectomy but later developed epiphora and nasolacrimal duct blockage.
  • Ten patients had radiotherapy and 14 had chemotherapy and radiotherapy before DCR.
  • The mean time between completion of radiotherapy and DCR was 24 months (median, 31.5 months), and the mean time between completion of chemotherapy and DCR was 21.5 months (median, 12.5 months).
  • In 1 of these 4 patients, tumor recurrence in the nasal cavity was the cause; he subsequently underwent a total rhinectomy.
  • The other 2 patients with recurrent blockage elected not to have additional surgery.
  • None of the patients who had had radiotherapy developed osteoradionecrosis.
  • Two patients had mild wound infections, which resolved after 1 week of systemic antibiotic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Atanasov DT, Indjov SI, Lalabonova HK, Neichev DS: Sarcomas of the mandible. Literature review and case reports. Folia Med (Plovdiv); 2004;46(2):31-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the mandible. Literature review and case reports.
  • The authors treated six patients with sarcomas of the mandible over a period of ten years: 2 patients with fibrosarcomas, 2 with lymphosarcomas, one with osteogenic sarcoma and one with chondrosarcoma.
  • The patients' ages ranged from 28 to 65 years, one was male and five - female.
  • The present study reports three cases (osteogenic sarcoma, fibrosarcoma, chondrosarcoma) with specific clinical and radiographic characteristics, demonstrating the differences between the various types of sarcomas.
  • Special attention is paid to the first clinical signs and symptoms, and to the differential diagnosis with inflammatory conditions (post-extraction alveolitis, chronic odontogenic osteomyelitis), benign tumors (osteoblastoclastoma, ameloblastoma, odontogenic cysts, fibrous dysplasia) and centrally developing jaw carcinomas.
  • Particular emphasis is given to CT imaging and morphological examinations in making an accurate diagnosis and providing adequate treatment.
  • Early diagnosis and precise surgical treatment (total resection or hemiexarticulation, or neck dissection if submandibular or cervical metastases are present) are essential to achieve satisfactory management of these malignant neoplasms.
  • The radiotherapy and chemotherapy administered according to the histologic features of the tumor are also of significance.
  • [MeSH-major] Chondrosarcoma / diagnosis. Fibrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15506548.001).
  • [ISSN] 0204-8043
  • [Journal-full-title] Folia medica
  • [ISO-abbreviation] Folia Med (Plovdiv)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Bulgaria
  • [Number-of-references] 21
  •  go-up   go-down


13. Van Dam SD, Unni KK, Keller EE: Metastasizing (malignant) ameloblastoma: review of a unique histopathologic entity and report of Mayo Clinic experience. J Oral Maxillofac Surg; 2010 Dec;68(12):2962-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing (malignant) ameloblastoma: review of a unique histopathologic entity and report of Mayo Clinic experience.
  • PURPOSE: To provide a comprehensive review of metastasizing (malignant) ameloblastoma, establish a new baseline of valid cases using histologic criteria and minimum documentation, and report 3 cases from the Mayo Clinic files.
  • PATIENTS AND METHODS: Ninety-eight original reports of "metastasizing," "malignant," or "atypical" ameloblastoma were reviewed.
  • The following data were gathered for reports that demonstrated well-differentiated ameloblastoma at the metastatic site: gender, ethnicity, age at time of primary tumor diagnosis, histologic pattern of primary tumor, anatomic sites of primary and metastatic tumors, interval from diagnosis of primary to diagnosis of metastasis, number of recurrences preceding metastasis, treatment responses to radiation and/or chemotherapy, presence of hypercalcemia, and length of survival after metastasis.
  • RESULTS: Twenty-seven valid reports of metastasizing (malignant) ameloblastoma were identified; 81% originated in the mandible, recurring on average 4 times before metastasis.
  • Lungs were the initial site of metastasis in 78% of reports, of which 71% were bilateral.
  • The average time from diagnosis of primary to metastasis was 18 years.
  • Over half of the patients were alive and had survived an average of 10 years since diagnosis of metastasis.
  • Those patients who had succumbed to their disease had an average survival time of 3 years after diagnosis of metastasis.
  • CONCLUSIONS: Metastasis of well-differentiated ameloblastoma occurs more rarely than previously believed.
  • Metastasis to the lungs bilaterally, by the hematogenous route, usually follows multiple failed attempts at primary tumor control.
  • Treatment of metastasizing (malignant) ameloblastoma should include close observation, thoracotomy with wedge resections, or experimental chemotherapeutic combinations.
  • [MeSH-major] Ameloblastoma / secondary. Lung Neoplasms / secondary. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Sex Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20970910.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


14. Grünwald V, Le Blanc S, Karstens JH, Weihkopf T, Kuske M, Ganser A, Schöffski P: Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin. Ann Oncol; 2001 Oct;12(10):1489-91
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin.
  • We report an unusual case of metastatic ameloblastoma, involving lung and pleura. that repeatedly responded to systemic treatment with paclitaxel and carboplatin. suggesting principle chemosensitivity of this rare disease.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762824.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Ricard AS, Majoufre-Lefebvre C, Siberchicot F, Laurentjoye M: A multirecurrent ameloblastoma metastatic to the lung. Rev Stomatol Chir Maxillofac; 2010 Apr;111(2):98-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multirecurrent ameloblastoma metastatic to the lung.
  • INTRODUCTION: The ameloblastoma is a rare tumor of odontogenic epithelial origin.
  • It is a neoplasm in which ameloblastic features are revealed by the primary growth in jaws and by any metastatic growth.
  • We present a case of a multirecurrent ameloblastoma of the mandible metastatic to the lung.
  • OBSERVATION: We present a case of a mandibular malignant ameloblastoma in a 42-year old man with widespread pulmonary metastases.
  • DISCUSSION: Ameloblastoma metastasis often occurs in the lung.
  • The curative treatment is surgical.
  • The results of palliative chemotherapy and radiotherapy are not always efficient.
  • [MeSH-major] Ameloblastoma / pathology. Ameloblastoma / secondary. Lung Neoplasms / secondary. Mandibular Neoplasms / pathology. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Transplantation. Humans. Lung / surgery. Male. Mandible / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20347463.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Dudek AZ, Murthaiah PK, Franklin M, Truskinovsky AM: Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor. Acta Oncol; 2010;49(1):101-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
  • [MeSH-major] Adamantinoma / drug therapy. Adamantinoma / pathology. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Pyrroles / therapeutic use
  • [MeSH-minor] Accidents, Traffic. Appendicitis / complications. Enzyme Inhibitors / therapeutic use. Foot / pathology. Fractures, Bone / complications. Humans. Immunohistochemistry. Male. Middle Aged. Psoriasis / complications. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Smoking. Tomography, X-Ray Computed. Vitamin B 12 Deficiency / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412810.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down






Advertisement